Sterling acquires US facility from Alcami
Pharmaceutical CDMO Sterling Pharma Solutions which is based near Newcastle-upon-Tyne, UK, and was formerly owned by Rhodia and Shasun, has acquired Alcami’s facility at Germantown, Wisconsin (pictured). Terms were not disclosed.
Sterling said that this will boost its API development and manufacturing capacity, particularly for complex and hazardous requirements, and including high potency. Germantown has cGMP development, scale-up and manufacturing facilities with specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.
Alcami itself has just completed several expansion projects, including the build-out of the sterile manufacturing site in Charleston, South Carolina, and the acquisition of TriPharm.
Sterling has also officially opened its new Material Science Centre (MSC). This will add solid form services that it had formerly outsourced, including salt and co-crystal screening, polymorph screening, preformulation evaluation and crystallisation development, within its in-house capabilities.
The MSC comprises six ISO Class 8 cleanrooms, with four milling and micronisation suites, plus associated warehousing and workshop facilities. There are also fully equipped solid state laboratory and an analytical services laboratory and write-up area.
“The centre will allow us to manage more of the product processing and as a result improve efficiencies; mitigating risk and allowing us to provide our customers with more cost-effective solutions,” said CEO Kevin Cook.